Endocrine Abstracts

Introduction: Multifocality empirically is often treated as a risk factor for aggressive course of papillary thyroid carcinoma (PTC), encouraging aggressive treatments. However, inconsistency and even contradiction in a literature is present concerning the role of tumor multifocality in clinical outcomes of PTC. Therefore, the prognostic value of multifocality of PTC remains controversial, creating a difficulty in the current clinical management.Methods....

Introduction: Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid cancer, accounting for about 80% of all cases of thyroid cancer. Generally, PTC is an indolent disease and shows a good prognosis in most patients. However, up to 30% of patients have local tumor renewal or systemic spread. It is crucial to identify patients with a high risk of disease progression. DNA methylation biomarkers may provide clinically valuable information and improve ...

Introduction: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer (85%–90%). Today Fine needle aspiration biopsy (FNAB) is the diagnostic tool for the evaluation of thyroid nodules because of its accuracy and cost-effectiveness, but FNAB also has limitations, as it is quite challenging to take a biopsy from a small thyroid nodule moreover FNAB diagnosis is doubtful in up to 20% of cases. Therefore, non-invasive biomarkers of PTC are needed.<p clas...

Introduction: Improper management of papillary thyroid carcinoma (PTC) patients results in potentially higher fatal outcomes due to a lack of relevant prognostic markers, inadequate periodic individualized risk assessments and/or insufficient initial treatment. MiR-146b, -21, -221, -222, -181b are potential biomarkers for risk stratification in PTC.Aim: The aim of our study was to analyze expression levels of five miRNA molecules (miR-21; miR -221; miR -...

Introduction: The sensitivity and specificity of biomarkers which have been used in clinical practice for diagnosis of papillary thyroid carcinoma (PTC) are low. It is essential to develop novel diagnostic biomarkers for PTC.Objective: We aimed to explore the expression levels of miR-222, – 146b, –181b in PTC tissue and plasma samples and to compare with benign thyroid nodules (BTN).Methods: We collected plasma samples ...

IntroductionInadequately managed papillary thyroid carcinoma (PTC) patients result in potentially higher fatal outcomes due to a lack of sufficient prognostic data/markers, inadequate periodic individualized follow-up risk assessments and/or insufficient initial treatment. MiR-146b, -21, -221, -222, -181b are potential biomarkers for risk stratification of PTC.AimThe aim of our study was to analyze expression...